Relevant Articles About Bladder Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to investigate Nrf2-ARE genes in relation to CRF in postmenopausal women with early-stage BC. The study concluded that biomarkers based on Nrf2-ARE genes could potentially identify women at increased risk for severe CRF. To explore...
KEY TAKEAWAYS The observational study aimed to assess the molecular pathologic map of EOCRC by comparing it with LOCRC. Researchers observed that EOCRC has high MSI-H rates, specific mutations, and elevated PD-L1, guiding tailored treatments. The prognosis of...
KEY TAKEAWAYS The study aimed to evaluate the prognostic and immunotherapeutic potential of aneuploidy-related genes in patients with LUAD. The study provided an ARS model analysis that enhances LUAD diagnosis and novel therapeutics. Patients diagnosed with lung...
The CheckMate 274 phase 3 trial aimed to evaluate the long-term impact of adjuvant nivolumab on OS in patients with bladder cancer. The …
The phase 2 trial aimed to investigate the utility of uMRD profiling in predicting recurrence and assessing response to nadofaragene firadenovec therapy in …
The study aimed to present the updated result on efficacy of neoadjuvant N + I in cisplatin-ineligible patients with UTUC. The primary endpoint …
Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer …
Background Tertiary lymphoid structures (TLSs) are thought to stimulate antitumor immunity and positively impact prognosis and response to immune checkpoint blockade. In gastric cancers (GCs), however, TLSs are predominantly found in GC with poor prognosis and …
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods We compared the immune tumor microenvironment of MMRd …
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine …